Helena Yu, MD
Memorial Sloan Kettering Cancer Center
Research Project:
Developing a Model to Select Patients for Radiation Therapy in EGFR+ Lung Cancer
Grant Awarded:
- Lung Cancer Discovery Award
Research Topics:
- biomarkers
- clinical research
- imaging radiology
- modeling
Research Disease:
- lung cancer
Lung cancer with genetic changes in the epidermal growth factor receptor (EGFR) protein occurs in up to 20% of all lung cancers. Osimertinib is a targeted therapy tailored for these cancers. The treatment is initially effective, but lung cancer eventually adapts and regrows. No subsequent oral targeted therapies are available. Some patients have excellent responses to osimertinib but have a few areas where the cancer has remains. We found that radiation therapy can treat these lesions, extending disease control with osimertinib. However, there are no guidelines for selecting patients for radiation therapy, a treatment that has potentially serious side effects. With our unique access to patients and samples, we will use advanced imaging techniques and circulating tumor DNA in the blood to develop a model that accurately predicts response to osimertinib in order to select patients for radiation therapy either at maximum tumor shrinkage or at the time of tumor growth on osimertinib.
The Keith R. Ayres Lung Cancer Discovery Award
Page last updated: October 29, 2025
A Breath of Fresh Air in Your Inbox
Join over 700,000 people who receive the latest news about lung health, including research, lung disease, air quality, quitting tobacco, inspiring stories and more!
Thank You!
You will now receive email updates from the American Lung Association.
